HOME >> MEDICINE >> NEWS
New drug holds promise to block clots in people with artery disease

DALLAS, April 30 The first study of a new drug designed to block blood clot formation showed no major adverse effects in people with stable coronary artery disease, according to a report in todays rapid access issue of Circulation: Journal of the American Heart Association.

The compound, DX-9065a, inhibits the action of factor Xa, one of the thirteen known factors involved in forming blood clots in coronary arteries. Factor Xa activates an enzyme called thrombin, which promotes the conversion of fibrinogen into fibrin, a major component of blood clots.

This is the first clinical experience with a direct, selective, reversible factor Xa inhibitor in patients with coronary artery disease, says cardiology researcher Robert A. Harrington, M.D., of the Duke Clinical Research Institute, in Durham, N.C. Our findings should lay the groundwork for further investigation of this and other agents that inhibit factor Xa in people with atherothrombosis, ischemic heart disease, and those undergoing coronary bypass surgery.

Anticoagulants, or blood-thinning drugs, work by inhibiting the ability of the blood to clot. Blood clots lodged in the coronary arteries block blood flow to the heart and cause most heart attacks. Anticoagulant therapy is commonly prescribed for people with heart disease to prevent further clot formation. The biggest drawback for anticoagulant drugs has been the potential for bleeding complications The randomized, double blind, placebo-controlled study, dubbed XaNADU, involved 73 patients with stable coronary artery disease at 10 medical centers. Their median age was 63 years, and 29 percent were women. Most had suffered a prior heart attack or had undergone angioplasty or coronary artery bypass surgery. During the study, 15 patients received a placebo, while 58 people received one of four different doses of DX-9065a, administered continuously over 72 hours.

Incidence of bleeding was minor and usually around the inf
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
29-Apr-2002


Page: 1 2

Related medicine news :

1. Chemical cousin of anti-anxiety drugs holds promise for psoriasis treatment
2. Direct payments to households in poor countries could improve maternal & child health
3. Worlds largest scientific society holds regional meeting Sept. 29 - Oct. 2 in Fort Worth
4. Case Western Reserves Flight Nursing Academy holds camp for nurses in air medical services
5. Optical glucose sensor holds promise for diabetics and intensive care patients
6. Intl Assoc for Dental Research holds 83rd General Session
7. Blood-diverting catheter holds promise for stroke treatment
8. Overweight and obesity thresholds may be misleading for Asian populations
9. Baclofen holds promise for cocaine treatment
10. Study shows combining gene therapy and radiation holds promise
11. Drug holds promise as an alternative for sickle cell patients unable to tolerate standard treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology:
Cached News: